The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 16, 2026
Snapshot (as of Oct 16, 2026): Eli Lilly and Company (LLY) pays a $6.46 annual dividend ($1.73 quarterly), yielding 0.59% at $1251.61/share. Next ex-dividend date 2026-08-14. 52+ consecutive years of dividend growth (Dividend King). Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 0.59%
Annual Dividend: $6.46 per share
Payout Ratio: 21.7%
Ex-Dividend Date: 2026-08-14
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 55
Eli Lilly and Company dividend investors are looking at one of the longest-running payers in the pharmaceutical sector, backed by blockbuster products like Mounjaro, Zepbound, and Verzenio. The current yield is 0.59%, with trailing twelve-month payments of $6.46 per share paid quarterly. The next ex-dividend date is August 14, 2026, with the last declared payment at $1.73 per share. LLY suits growth-and-income investors more than pure income seekers, given its 52-year streak of consecutive dividend increases and a beta of 0.453 that reflects relatively low price volatility.
Eli Lilly and Company pays out 21.7% of earnings as dividends, a payout ratio classified as conservative (below 40%). That low payout leaves substantial room to sustain and grow the dividend, supported by a broad product portfolio spanning high-demand categories like GLP-1 therapies for type 2 diabetes and obesity, where Mounjaro and Zepbound have driven rapid revenue expansion. Eli Lilly and Company dividend safety faces its most credible pressure from the pharmaceutical industry's inherent exposure to patent cliffs and pipeline risk, where a single product's loss of exclusivity can materially shift earnings.
Over the past 14 years, Eli Lilly and Company dividend history shows a CAGR of 8.3% per year from 2011 to 2025. The per-share annual dividend grew from $1.96 to $6.00 over that period (2026 data is partial and excluded from this calculation). The largest annual increase in the window was 15.4% in 2025, while the smallest increases came in the 2012-2014 period, when the dividend held flat at $1.96 per share for three consecutive years.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +15.2% | $3.92 (2022) | $6.00 (2025) |
| 5-Year | +15.2% | $2.96 (2020) | $6.00 (2025) |
| 10-Year | +11.6% | $2.00 (2015) | $6.00 (2025) |
LLY is a Dividend King built for investors who want dividend growth, not maximum current income. The yield sits at a low (below 2%) 0.59%, which is actually below its own 5-year average of 0.76%, meaning the stock's price appreciation has outpaced dividend growth in recent years. That said, 52 consecutive years of dividend increases is a rare achievement, and an 8.3% annual growth rate over 14 years is meaningful compounding for a long-horizon investor. The trade-off is straightforward: Eli Lilly and Company delivers a rising dividend with a conservative payout ratio, but investors accept a very low starting yield in exchange for that growth.
LLY is a Dividend King — 52 consecutive years of dividend increases.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-14 | $1.7300 |
| 2026-05-15 | $1.7300 |
| 2026-02-13 | $1.7300 |
| 2025-11-14 | $1.5000 |
| 2025-08-15 | $1.5000 |
| 2025-05-16 | $1.5000 |
| 2025-02-14 | $1.5000 |
| 2024-11-15 | $1.3000 |
| 2024-08-15 | $1.3000 |
| 2024-05-15 | $1.3000 |
| Year | Total Dividends |
|---|---|
| 2026 | $5.1900 |
| 2025 | $6.0000 |
| 2024 | $5.2000 |
| 2023 | $4.5200 |
| 2022 | $3.9200 |
Project income from LLY with the LLY dividend calculator or track your full portfolio with the dividend tracker.